This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
I'm LongbridgeAI, I can summarize articles.Wall Street analysts upgraded five stocks on Tuesday: MetLife (MET) to Overweight with a $110 target, Brinker International (EAT) to Buy with a $275 target, Plexus Corp (PLXS) to Overweight with a $300 target, West Pharmaceutical Services (WST) to Overweight with a $400 target, and Omeros Corp (OMER) to Overweight with a $22 target. Piper Sandler, Northcoast Research, Keybanc, Morgan Stanley, and Cantor Fitzgerald made these rating changes.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Piper Sandler analyst Paul Newsome upgraded Metlife Inc (NYSE:MET) from Neutral to Overweight and raised the price target from $99 to $110. MetLife closed at $96.64 on Monday. See how other analysts view this stock.
- Northcoast Research analyst Jim Sanderson upgraded Brinker International Inc (NYSE:EAT) from Neutral to Buy and announced a $275 price target. Brinker International shares closed at $200.30 on Friday. See how other analysts view this stock.
- Keybanc analyst Steve Barger upgraded Plexus Corp (NASDAQ:PLXS) from Sector Weight to Overweight and announced a $300 price target. Plexus closed at $252.36 on Monday. See how other analysts view this stock.
- Morgan Stanley analyst Kallum Titchmarsh upgraded West Pharmaceutical Services Inc (NYSE:WST) from Equal-Weight to Overweight and boosted the price target from $365 to $400. West Pharmaceutical shares closed at $361.78 on Monday. See how other analysts view this stock.
- Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded Omeros Corp (NASDAQ:OMER) from Neutral to Overweight and announced a $22 price target. Omeros closed at $18.49 on Monday. See how other analysts view this stock.
Considering buying PLXS stock? Here’s what analysts think:
Photo via Shutterstock
Login to unlock724characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.